BiSpecific MAbS - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510245829

Publication Date:

October 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for BiSpecific MAbS was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for BiSpecific MAbS was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for BiSpecific MAbS was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for BiSpecific MAbS was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of BiSpecific MAbS include Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Bristol Myers Squibb and Abbott, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for BiSpecific MAbS, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of BiSpecific MAbS by region & country, by Type, and by Application.
The BiSpecific MAbS market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding BiSpecific MAbS.
Market Segmentation
By Company
Johnson & Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S
Bayer AG
Thermo Fisher Scientific
Bristol Myers Squibb
Abbott
Segment by Type:
Catumaxomab (Removab鈩�)
Blinatumomab
Emicizumab
Amivantamab
Others
Segment by Application
Hospital
Research Institute
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of BiSpecific MAbS manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of BiSpecific MAbS in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of BiSpecific MAbS in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 BiSpecific MAbS Product Introduction
1.2 Global BiSpecific MAbS Market Size Forecast
1.3 BiSpecific MAbS Market Trends & Drivers
1.3.1 BiSpecific MAbS Industry Trends
1.3.2 BiSpecific MAbS Market Drivers & Opportunity
1.3.3 BiSpecific MAbS Market Challenges
1.3.4 BiSpecific MAbS Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global BiSpecific MAbS Players Revenue Ranking (2023)
2.2 Global BiSpecific MAbS Revenue by Company (2019-2024)
2.3 Key Companies BiSpecific MAbS Manufacturing Base Distribution and Headquarters
2.4 Key Companies BiSpecific MAbS Product Offered
2.5 Key Companies Time to Begin Mass Production of BiSpecific MAbS
2.6 BiSpecific MAbS Market Competitive Analysis
2.6.1 BiSpecific MAbS Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by BiSpecific MAbS Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in BiSpecific MAbS as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Catumaxomab (Removab鈩�)
3.1.2 Blinatumomab
3.1.3 Emicizumab
3.1.4 Amivantamab
3.1.5 Others
3.2 Global BiSpecific MAbS Sales Value by Type
3.2.1 Global BiSpecific MAbS Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global BiSpecific MAbS Sales Value, by Type (2019-2030)
3.2.3 Global BiSpecific MAbS Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Research Institute
4.1.3 Others
4.2 Global BiSpecific MAbS Sales Value by Application
4.2.1 Global BiSpecific MAbS Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global BiSpecific MAbS Sales Value, by Application (2019-2030)
4.2.3 Global BiSpecific MAbS Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global BiSpecific MAbS Sales Value by Region
5.1.1 Global BiSpecific MAbS Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global BiSpecific MAbS Sales Value by Region (2019-2024)
5.1.3 Global BiSpecific MAbS Sales Value by Region (2025-2030)
5.1.4 Global BiSpecific MAbS Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America BiSpecific MAbS Sales Value, 2019-2030
5.2.2 North America BiSpecific MAbS Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe BiSpecific MAbS Sales Value, 2019-2030
5.3.2 Europe BiSpecific MAbS Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific BiSpecific MAbS Sales Value, 2019-2030
5.4.2 Asia Pacific BiSpecific MAbS Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America BiSpecific MAbS Sales Value, 2019-2030
5.5.2 South America BiSpecific MAbS Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa BiSpecific MAbS Sales Value, 2019-2030
5.6.2 Middle East & Africa BiSpecific MAbS Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions BiSpecific MAbS Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions BiSpecific MAbS Sales Value
6.3 United States
6.3.1 United States BiSpecific MAbS Sales Value, 2019-2030
6.3.2 United States BiSpecific MAbS Sales Value by Type (%), 2023 VS 2030
6.3.3 United States BiSpecific MAbS Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe BiSpecific MAbS Sales Value, 2019-2030
6.4.2 Europe BiSpecific MAbS Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe BiSpecific MAbS Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China BiSpecific MAbS Sales Value, 2019-2030
6.5.2 China BiSpecific MAbS Sales Value by Type (%), 2023 VS 2030
6.5.3 China BiSpecific MAbS Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan BiSpecific MAbS Sales Value, 2019-2030
6.6.2 Japan BiSpecific MAbS Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan BiSpecific MAbS Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea BiSpecific MAbS Sales Value, 2019-2030
6.7.2 South Korea BiSpecific MAbS Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea BiSpecific MAbS Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia BiSpecific MAbS Sales Value, 2019-2030
6.8.2 Southeast Asia BiSpecific MAbS Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia BiSpecific MAbS Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India BiSpecific MAbS Sales Value, 2019-2030
6.9.2 India BiSpecific MAbS Sales Value by Type (%), 2023 VS 2030
6.9.3 India BiSpecific MAbS Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Profile
7.1.2 Johnson & Johnson Main Business
7.1.3 Johnson & Johnson BiSpecific MAbS Products, Services and Solutions
7.1.4 Johnson & Johnson BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.1.5 Johnson & Johnson Recent Developments
7.2 Novartis AG
7.2.1 Novartis AG Profile
7.2.2 Novartis AG Main Business
7.2.3 Novartis AG BiSpecific MAbS Products, Services and Solutions
7.2.4 Novartis AG BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.2.5 Novartis AG Recent Developments
7.3 Hoffmann-La Roche Ltd.
7.3.1 Hoffmann-La Roche Ltd. Profile
7.3.2 Hoffmann-La Roche Ltd. Main Business
7.3.3 Hoffmann-La Roche Ltd. BiSpecific MAbS Products, Services and Solutions
7.3.4 Hoffmann-La Roche Ltd. BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.3.5 Novo Nordisk A/S Recent Developments
7.4 Novo Nordisk A/S
7.4.1 Novo Nordisk A/S Profile
7.4.2 Novo Nordisk A/S Main Business
7.4.3 Novo Nordisk A/S BiSpecific MAbS Products, Services and Solutions
7.4.4 Novo Nordisk A/S BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.4.5 Novo Nordisk A/S Recent Developments
7.5 Bayer AG
7.5.1 Bayer AG Profile
7.5.2 Bayer AG Main Business
7.5.3 Bayer AG BiSpecific MAbS Products, Services and Solutions
7.5.4 Bayer AG BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.5.5 Bayer AG Recent Developments
7.6 Thermo Fisher Scientific
7.6.1 Thermo Fisher Scientific Profile
7.6.2 Thermo Fisher Scientific Main Business
7.6.3 Thermo Fisher Scientific BiSpecific MAbS Products, Services and Solutions
7.6.4 Thermo Fisher Scientific BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.6.5 Thermo Fisher Scientific Recent Developments
7.7 Bristol Myers Squibb
7.7.1 Bristol Myers Squibb Profile
7.7.2 Bristol Myers Squibb Main Business
7.7.3 Bristol Myers Squibb BiSpecific MAbS Products, Services and Solutions
7.7.4 Bristol Myers Squibb BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.7.5 Bristol Myers Squibb Recent Developments
7.8 Abbott
7.8.1 Abbott Profile
7.8.2 Abbott Main Business
7.8.3 Abbott BiSpecific MAbS Products, Services and Solutions
7.8.4 Abbott BiSpecific MAbS Revenue (US$ Million) & (2019-2024)
7.8.5 Abbott Recent Developments
8 Industry Chain Analysis
8.1 BiSpecific MAbS Industrial Chain
8.2 BiSpecific MAbS Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 BiSpecific MAbS Sales Model
8.5.2 Sales Channel
8.5.3 BiSpecific MAbS Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Johnson & Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S
Bayer AG
Thermo Fisher Scientific
Bristol Myers Squibb
Abbott

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂